Pirfenidone for Idiopathic Pulmonary Fibrosis
Pirfenidone is FDA-approved for IPF and should be dosed at 801 mg three times daily (2,403 mg/day total) after a 14-day titration period, taken with food to minimize gastrointestinal side effects. 1
Dosing Protocol
Initial Titration (Mandatory 14-Day Period)
- Days 1-7: 267 mg three times daily (801 mg/day)
- Days 8-14: 534 mg three times daily (1,602 mg/day)
- Day 15 onward: 801 mg three times daily (2,403 mg/day) 1
Critical administration rule: All doses must be taken with food at the same time each day. Taking pirfenidone during a substantial meal is more effective at mitigating gastrointestinal adverse events than taking it with light snacks 2.
Alternative Titration for Intolerance
While the FDA label specifies a 14-day titration, real-world practice shows that approximately 75% of pulmonologists use alternative schedules when patients experience GI intolerance, with 4-week titrations being most common (up to 8 weeks in some cases). Most patients using these extended schedules can still achieve full dosing 2. However, only 42.6% of patients tolerate the full 2,403 mg/day dose in real-world settings 3.
Monitoring Requirements
Baseline Testing (Before Starting)
- Liver function tests: ALT, AST, and bilirubin 1
Ongoing Monitoring
- Liver enzymes: Monitor ALT, AST, and bilirubin regularly during treatment 1
- Lung function: Track FVC decline to assess treatment efficacy 4
Dosage Modifications for Adverse Events
Hepatotoxicity Management
ALT/AST >3 but ≤5 × ULN without symptoms:
- Discontinue confounding medications
- Exclude other causes
- May maintain full dose if clinically appropriate, OR reduce/interrupt until liver tests normalize, then re-titrate 1
ALT/AST >3 but ≤5 × ULN WITH symptoms or hyperbilirubinemia:
- Permanently discontinue pirfenidone
- Do not rechallenge 1
ALT/AST >5 × ULN:
- Permanently discontinue pirfenidone
- Do not rechallenge 1
Treatment Interruptions
- <14 days missed: Resume previous dose
- ≥14 days missed: Restart with full 14-day titration regimen 1
Gastrointestinal Adverse Events
Consider temporary dose reduction or interruption for significant nausea, vomiting, diarrhea, dyspepsia, or abdominal pain. These are the most common adverse events (nausea occurs in 36% vs 17% placebo) 4. Once symptoms resolve, re-titrate to full dose as tolerated 1.
Photosensitivity and Rash
- Occurs in 12% of patients (vs 2% placebo) 4
- Recommend: daily sunscreen use, sun avoidance, wearing hats, and UV-protective clothing 2
- Consider temporary dose reduction or interruption for severe reactions 1
Severe Cutaneous Adverse Reactions (SCAR)
If Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS is confirmed:
- Permanently discontinue pirfenidone 1
Drug Interactions Requiring Dose Adjustment
Strong CYP1A2 Inhibitors (e.g., fluvoxamine, enoxacin)
- Reduce to 267 mg three times daily (801 mg/day) 1
- Alternatively, discontinue the inhibitor before starting pirfenidone
Moderate CYP1A2 Inhibitors (e.g., ciprofloxacin 750 mg twice daily)
- Reduce to 534 mg three times daily (1,602 mg/day) 1
CYP1A2 Inducers (e.g., smoking, omeprazole)
- May require dose adjustments to maintain therapeutic levels 5
Contraindications
None listed in FDA labeling 1. However, use clinical judgment in patients with:
- Severe hepatic impairment (requires dose adjustment) 5
- BMI <20 kg/m² (higher risk of discontinuation due to adverse events) 3
Alternatives
For IPF
Nintedanib is the primary alternative antifibrotic agent for IPF. It has similar efficacy in slowing FVC decline but a different adverse event profile:
- More gastrointestinal side effects than pirfenidone (diarrhea 2.8×, nausea 3.1×, vomiting 3.6×) 6
- Higher rate of dose reduction (7.9× vs placebo) 6
- Discontinuation rate similar to pirfenidone (16.2% vs 16.6%) 7
For Progressive Pulmonary Fibrosis (Non-IPF ILD)
The 2022 ATS/ERS/JRS/ALAT guidelines provide different recommendations:
Nintedanib: Conditional recommendation FOR use in PPF after failed standard management (low-quality evidence) 6
Pirfenidone: No recommendation made—additional research recommended. The guideline committee vote showed 62% conditional support, but 38% abstained citing insufficient evidence 6. Only 380 patients with PPF (253 with fibrotic uILD) have been studied in randomized trials 6.
Clinical Efficacy Considerations
Full-dose therapy (2,403 mg/day) appears necessary for survival benefit. Real-world data shows improved survival with full-dose pirfenidone (HR 0.19, p=0.045) but not with reduced doses (p=0.08) compared to no treatment 3. The EC80 (concentration achieving 80% of maximum effect) corresponds to approximately 1,500-1,800 mg/day based on pharmacokinetic modeling 8, though clinical outcomes data favor full dosing.
Common Pitfalls
- Not taking with food: This significantly increases GI adverse events
- Inadequate sun protection counseling: Photosensitivity is predictable and preventable
- Abandoning therapy too quickly: Many adverse events are manageable with temporary dose reduction rather than permanent discontinuation
- Using reduced doses long-term: May compromise survival benefit 3
- Failing to re-titrate after interruptions ≥14 days: Increases risk of adverse events